Navigation Links
Epeius Biotechnologies Receives Notice of Patent Allowance for Tumor-Targeted Cancer Vaccines

SAN MARINO, Calif., March 16 /PRNewswire/ -- Epeius Biotechnologies Corporation, an emerging leader in the field of targeted genetic medicine, received a notice of allowance from the USPTO for a crucial patent covering its leading tumor-targeted vaccine technology for cancer immunotherapy. The issuance of this valuable patent protection for tumor targeted immunotherapy follows on the heels of two international patents covering targeted gene medicine in the U.S. and Europe, respectively, and places Epeius Biotech at the forefront of these emerging fields of clinical medicine with best-of-breed solutions and incontrovertible proofs-of-principle in the clinic.

The advent of pathotropic (disease-seeking) targeting technology first enabled the development of  tumor-targeted Rexin-G, which seeks-out, accumulates-in, and selectively delivers a lethal designer gene to tumors that have spread throughout the body (metastatic cancer), halting the progression of disease while improving both survival and quality-of-life. Approved for all solid tumors in the Philippines, Rexin-G has received Orphan Drug and Fast Track status from the U.S. FDA, and is currently moving on to Phase III trials for first-line and second-line indications.  Once the control of tumor growth has been achieved with Rexin-G, the need to extend the treatment intervals and/or clinical remissions led to the development of Reximmune-C, a second tumor-targeted genetic medicine which delivers a pulse of immune-stimulating cytokine directly to the sites of residual or recurrent disease, thereby recruiting the patient's own immune system into the lesions of the residual cancer to invoke a more lasting anti-tumor immune response.

Much like a SWAT (special weapons and tactics) Team that calls an elite police force to the scene of a crime, Reximmune-C acts at the local level, recruiting the body's own professional immune cells, antigen-presenting cells, helper cells, and killer T-cells directly to the locus of the residual cancer, where tumor debris as antigens are abundant.  This provides the patient with an opportunity to mount a beneficial immune response that would further improve clinical outcome. Unlike, previous approaches to personalized cancer vaccination, a simple intravenous infusion of tumor-targeted Reximmune-C marshals the cadre of complex immunological responses of this intrinsic SWAT Team to the place where it is needed most.  By reaching beyond the boundaries of medicine to the very crux of metastatic disease, Epeius delivers another vital innovation.

About Epeius Biotechnologies:

Epeius Biotechnologies Corporation is a privately held biopharmaceutical company dedicated to the advancement of genetic medicine with the development and commercialization of its leading oncology products and its tumor-targeted delivery systems.

To learn more about our pipeline of proprietary biotechnologies, please visit us at .

*(LOGO 72dpi:  

This release was issued on behalf of the above organization by Send2Press(R), a unit of Neotrope(R).

SOURCE Epeius Biotechnologies

Back to top



SOURCE Epeius Biotechnologies
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Epeius Biotechnologies Applauds the Belated Scholarship of Their Academic Contemporaries in 2007, As Targeted Gene Therapy Comes of Age in Clinical Medicine
2. ASEAN News: Epeius Biotechnologies Gains Commercial Approval for Rexin-G(R), a Tumor-Targeted Gene-Based Medicine for Metastatic Cancer
3. Howard Goldstein Joins Microchip Biotechnologies, Inc. as Executive Vice President
4. TriLink BioTechnologies, Inc. Announces Supply Agreement With Osmetech Molecular Diagnostics
5. Athera Biotechnologies and Dyax Announce a Collaboration to Discover and Develop Antibodies for Cardiovascular Inflammation
6. Watson Receives FDA Approval for Generic Cardizem(R) LA
7. ADVENTRX Receives Brand Name Acceptance for ANX-530
8. CEL-SCI Receives Payment From Marketing Partner
9. International Growth Continues: Rhythmlink International, LLC Receives CE Marking & ISO 13485 Certification
10. ISTA Pharmaceuticals Receives Action Date for FDA Review of Once-Daily XiDay(TM)
11. GelFix(TM) Posterior Spinal Distraction Implant Receives CE Mark
Post Your Comments:
(Date:6/24/2016)... Tenn. , June 24, 2016  Arkis ... providing less invasive and more durable cerebrospinal fluid ... in funding.  The Series-A funding is led by ... Lighthouse Fund, and other private investors.  Arkis, new ... neurosurgical instrumentation and the market release of its ...
(Date:6/23/2016)... , June 23, 2016 ... "Pharmaceutical Excipients Market by Type (Organic Chemical (Sugar, ... Formulation (Oral, Topical, Coating, Parenteral) - Global Forecast to ... The global pharmaceutical excipients market ... at a CAGR of 6.1% in the forecast period ...
(Date:6/23/2016)... June 23, 2016 Capricor ... ), a biotechnology company focused on the discovery, ... that patient enrollment in its ongoing randomized HOPE-Duchenne ... exceeded 50% of its 24-patient target. Capricor expects ... third quarter of 2016, and to report top ...
Breaking Medicine Technology:
(Date:6/27/2016)... Aliso Viejo, California (PRWEB) , ... June 27, 2016 , ... ... that are fully customizable inside of Final Cut Pro X," said Christina Austin - ... with another unique style. Final Cut Pro X users can now reveal ...
(Date:6/26/2016)... ... , ... Quality metrics are proliferating in cancer care, and are derived from ... of the beholder, according to experts who offered insights and commentary in the current ... For the full issue, click here . , For the American Society of ...
(Date:6/26/2016)... ... June 26, 2016 , ... ... have been diagnosed with endometriosis. These women need a treatment plan to not ... comprehensive approach that can help for preservation of fertility and ultimately achieving a ...
(Date:6/25/2016)... ... June 25, 2016 , ... First Choice Emergency Room ... Dr. Sesan Ogunleye, as the Medical Director of its new Mesquite-Samuell Farm facility. ... of our new Mesquite location,” said Dr. James M. Muzzarelli, Executive Medical Director of ...
(Date:6/24/2016)... ... June 24, 2016 , ... A recent article published June 14 ... The article goes on to state that individuals are now more comfortable seeking to ... operations such as calf and cheek reduction. The Los Angeles area medical group, Beverly ...
Breaking Medicine News(10 mins):